Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0167)
Name
Biochanin A
Synonyms
biochanin A; 491-80-5; Biochanin; 4'-Methylgenistein; 5,7-Dihydroxy-4'-methoxyisoflavone; 5,7-Dihydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one; olmelin; Pratensol; Biochanine A; Genistein 4-methyl ether; 5,7-dihydroxy-3-(4-methoxyphenyl)chromen-4-one; 4-Methylgenistein; 5,7-Dihydrox -4'-methoxyisoflavone; Biochanin-A; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-methoxyphenyl)-; NSC 123538; CCRIS 5449; NSC-123538; Isoflavone, 5,7-dihydroxy-4'-methoxy-; Genistein 4'-methyl ether; EINECS 207-744-7; NSC123538; UNII-U13J6U390T; 5,7-Dihydroxy-3-p-methoxyphenyl-4H-chromen-4-one; DTXSID1022394; CHEBI:17574; U13J6U390T; MFCD00006839; MLS000069443; CHEMBL131921; DTXCID102394; 4'-Methoxy-5,7-dihydroxy isoflavone; 5,7-dihydroxy-3-(4-methoxyphenyl)-4H-1-benzopyran-4-one; SMR000059116; BIOCHANIN A (USP-RS); BIOCHANIN A [USP-RS]; CAS-491-80-5; SR-01000003021; BiochaninA; QSO; Biochanin A, 9; 5,7-dihydroxy-4'-methoxy-Isoflavone; Biochanin A (BCA); Spectrum_000195; Genistein 4-Methylether; Opera_ID_621; Spectrum2_000047; Spectrum3_001098; Spectrum4_001927; Spectrum5_001624; BIOCHANIN A [MI]; Oprea1_038096; SCHEMBL61258; BSPBio_002776; KBioGR_002274; KBioSS_000675; MLS001148446; MLS006011785; BIDD:ER0123; DivK1c_001027; SPBio_000173; BDBM9461; GTPL2829; SPECTRUM10100003; Biochanin A (4-Methylgenistein); Biochanin A - 4-Methylgenistein; cid_5280373; HMS503M15; KBio1_001027; KBio2_000675; KBio2_003243; KBio2_005811; KBio3_001996; NINDS_001027; HMS2232N19; HMS3369A02; HMS3656A13; TNP00319; Isoflavone,7-dihydroxy-4'-methoxy-; Tox21_202097; Tox21_302901; BBL010523; CCG-38351; LMPK12050229; s2377; STK888295; AKOS002163860; DB15334; IDI1_001027; SMP1_000045; NCGC00017369-01; NCGC00017369-02; NCGC00017369-03; NCGC00017369-04; NCGC00017369-05; NCGC00017369-06; NCGC00017369-07; NCGC00017369-08; NCGC00017369-09; NCGC00017369-10; NCGC00022428-03; NCGC00022428-04; NCGC00022428-05; NCGC00178478-01; NCGC00256458-01; NCGC00259646-01; AC-22309; AS-17474; HY-14595; NCI60_000558; Biochanin A, analytical reference material; B4098; FT-0663120; SW219333-1; 5,7-dihydroxy-4'-methoxy-Isoflavone (8CI); BIOCHANIN A (CONSTITUENT OF RED CLOVER); C00814; Q864222; Q-100552; SR-01000003021-4; SR-01000003021-5; BIOCHANIN A (CONSTITUENT OF RED CLOVER) [DSC]; BRD-K73303757-001-02-6; BRD-K73303757-001-12-5; 5,7-Dihydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one #; F1190-0491; 4H-1-Benzopyran-4-one,7-dihydroxy-3-(4-methoxyphenyl)-; 2AA2D226-B323-4AE2-B576-2D47D15F9845; Biochanin A, United States Pharmacopeia (USP) Reference Standard

    Click to Show/Hide
Status
Investigative
Drug Type
Small molecular drug
Structure
Formula
C16H12O5
IUPAC Name
5,7-dihydroxy-3-(4-methoxyphenyl)chromen-4-one
Canonical SMILES
COC1=CC=C(C=C1)C2=COC3=CC(=CC(=C3C2=O)O)O
InChI
InChI=1S/C16H12O5/c1-20-11-4-2-9(3-5-11)12-8-21-14-7-10(17)6-13(18)15(14)16(12)19/h2-8,17-18H,1H3
InChIKey
WUADCCWRTIWANL-UHFFFAOYSA-N
PubChem CID
5280373
TTD Drug ID
D0S9YX
Full List of Ferroptosis Target Related to This Drug
Transferrin receptor protein 1 (TFRC)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Driver
Responsed Disease Knee osteoarthritis ICD-11: FA01
 Disease Info 
Pathway Response Ferroptosis hsa04216
Fatty acid metabolism hsa01212
Cell Process Cell ferroptosis
In Vitro Model hCDs (Chondrocytes)
In Vivo Model
Male mice were purchased from Guangzhou University of Chinese Medicine's Experimental Animal Center C57BL/6 mice (7-week-old, 20 g) (Guangzhou, China). After one week of adaptively feeding with chow meals and sterilized water, the animals were separated into five groups of ten mice randomly assigned to the negative control (NC); model, positive control (PC); model group; high dosage of BCA treatment (BCA-H) group; and low dosage of BCA treatment (BCA-L) group. The iron overload mice model was designed based on earlier research. Except for the NC group, mice were administered ID intraperitoneally (500 mg/kg) once a week for eight weeks. In the right knee joints, OA was induced with the initial injection of iron dextran two weeks after the injection by destabilizing the medial meniscus (DMM) using a microscope. After the operation, the positive control group was administered with NAC intragastrically (100 mg/kg) for eight weeks. BCA-H and BCA-L groups were administered 20 mg/kg and 40 mg/kg of BCA separately for eight weeks according to previous studies.

    Click to Show/Hide
Response regulation Biochanin A (BCA) could directly reduce intracellular iron concentration by inhibiting TfR1 and promoting FPN but also target the Nrf2/system xc-/GPX4 signaling pathway to scavenge free radicals and prevent lipid peroxidation. The results of this research indicate that BCA regulates iron homeostasis during the progression of osteoarthritis, which can open a new field of treatment for knee osteoarthritis.
Solute carrier family 40 member 1 (SLC40A1)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Knee osteoarthritis ICD-11: FA01
 Disease Info 
Pathway Response Ferroptosis hsa04216
Fatty acid metabolism hsa01212
Cell Process Cell ferroptosis
In Vitro Model hCDs (Chondrocytes)
In Vivo Model
Male mice were purchased from Guangzhou University of Chinese Medicine's Experimental Animal Center C57BL/6 mice (7-week-old, 20 g) (Guangzhou, China). After one week of adaptively feeding with chow meals and sterilized water, the animals were separated into five groups of ten mice randomly assigned to the negative control (NC); model, positive control (PC); model group; high dosage of BCA treatment (BCA-H) group; and low dosage of BCA treatment (BCA-L) group. The iron overload mice model was designed based on earlier research. Except for the NC group, mice were administered ID intraperitoneally (500 mg/kg) once a week for eight weeks. In the right knee joints, OA was induced with the initial injection of iron dextran two weeks after the injection by destabilizing the medial meniscus (DMM) using a microscope. After the operation, the positive control group was administered with NAC intragastrically (100 mg/kg) for eight weeks. BCA-H and BCA-L groups were administered 20 mg/kg and 40 mg/kg of BCA separately for eight weeks according to previous studies.

    Click to Show/Hide
Response regulation Biochanin A (BCA) could directly reduce intracellular iron concentration by inhibiting TfR1 and promoting FPN but also target the Nrf2/system xc-/GPX4 signaling pathway to scavenge free radicals and prevent lipid peroxidation. The results of this research indicate that BCA regulates iron homeostasis during the progression of osteoarthritis, which can open a new field of treatment for knee osteoarthritis.
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Knee osteoarthritis ICD-11: FA01
 Disease Info 
Pathway Response Ferroptosis hsa04216
Fatty acid metabolism hsa01212
Cell Process Cell ferroptosis
In Vitro Model hCDs (Chondrocytes)
In Vivo Model
Male mice were purchased from Guangzhou University of Chinese Medicine's Experimental Animal Center C57BL/6 mice (7-week-old, 20 g) (Guangzhou, China). After one week of adaptively feeding with chow meals and sterilized water, the animals were separated into five groups of ten mice randomly assigned to the negative control (NC); model, positive control (PC); model group; high dosage of BCA treatment (BCA-H) group; and low dosage of BCA treatment (BCA-L) group. The iron overload mice model was designed based on earlier research. Except for the NC group, mice were administered ID intraperitoneally (500 mg/kg) once a week for eight weeks. In the right knee joints, OA was induced with the initial injection of iron dextran two weeks after the injection by destabilizing the medial meniscus (DMM) using a microscope. After the operation, the positive control group was administered with NAC intragastrically (100 mg/kg) for eight weeks. BCA-H and BCA-L groups were administered 20 mg/kg and 40 mg/kg of BCA separately for eight weeks according to previous studies.

    Click to Show/Hide
Response regulation Biochanin A (BCA) could directly reduce intracellular iron concentration by inhibiting TfR1 and promoting FPN but also target the Nrf2/system xc-/GPX4 signaling pathway to scavenge free radicals and prevent lipid peroxidation. The results of this research indicate that BCA regulates iron homeostasis during the progression of osteoarthritis, which can open a new field of treatment for knee osteoarthritis.
Nuclear factor erythroid 2-related factor 2 (NFE2L2)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Marker/Suppressor
Responsed Disease Knee osteoarthritis ICD-11: FA01
 Disease Info 
Pathway Response Ferroptosis hsa04216
Fatty acid metabolism hsa01212
Cell Process Cell ferroptosis
In Vitro Model hCDs (Chondrocytes)
In Vivo Model
Male mice were purchased from Guangzhou University of Chinese Medicine's Experimental Animal Center C57BL/6 mice (7-week-old, 20 g) (Guangzhou, China). After one week of adaptively feeding with chow meals and sterilized water, the animals were separated into five groups of ten mice randomly assigned to the negative control (NC); model, positive control (PC); model group; high dosage of BCA treatment (BCA-H) group; and low dosage of BCA treatment (BCA-L) group. The iron overload mice model was designed based on earlier research. Except for the NC group, mice were administered ID intraperitoneally (500 mg/kg) once a week for eight weeks. In the right knee joints, OA was induced with the initial injection of iron dextran two weeks after the injection by destabilizing the medial meniscus (DMM) using a microscope. After the operation, the positive control group was administered with NAC intragastrically (100 mg/kg) for eight weeks. BCA-H and BCA-L groups were administered 20 mg/kg and 40 mg/kg of BCA separately for eight weeks according to previous studies.

    Click to Show/Hide
Response regulation Biochanin A (BCA) could directly reduce intracellular iron concentration by inhibiting TfR1 and promoting FPN but also target the Nrf2/system xc-/GPX4 signaling pathway to scavenge free radicals and prevent lipid peroxidation. The results of this research indicate that BCA regulates iron homeostasis during the progression of osteoarthritis, which can open a new field of treatment for knee osteoarthritis.
References
Ref 1 Biochanin A protects against iron overload associated knee osteoarthritis via regulating iron levels and NRF2/System xc-/GPX4 axis. Biomed Pharmacother. 2023 Jan;157:113915. doi: 10.1016/j.biopha.2022.113915. Epub 2022 Nov 12.